Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Credit

<ul><li>Amgen has continued to benefit from strong global demand for many of their innovative medicines, such as Repatha and Prolia, as well as their biosimilar offerings.</li><li>Teneobio's acquisition, when combined with Nuevolution's DNA encoded library technology, gives Amgen the ability to develop both large and small molecule multi-specifics.</li><li>Based on our credit analysis, the company merits a Credit Evaluation Score of BBβ with a stable outlook and as per our Financial Strength Indicator, its performance is 3.69/ 5.</li></ul>

Amgen has continued to benefit from strong global demand for many of their innovative medicines, such as Repatha and Prolia, as well as their biosimilar offerings.Teneobio's acquisition, when combined with Nuevolution's DNA encoded library technology, gives Amgen the ability to develop both large and small molecule multi-specifics.Based on our credit analysis, the company merits a Credit Evaluation Score of BBβ with a stable outlook and as per our Financial Strength Indicator, its performance is 3.69/ 5.

Amgen Inc.: Detailed Credit Analysis & Financial Strength Evaluation Report

Equity Capital Markets

<ul><li>Amgen experienced a decent quarter of growth, with total revenues up 4% and volume up 8%, reflecting strong global demand for many of their innovative medicines, such as Repatha and Prolia, as well as their biosimilar offerings.</li><li>The development of multi-specific drugs to make untractable targets tractable is one of its primary research and molecular engineering interests.</li><li>We remain optimistic about Amgen’s future growth and maintain our 'Hold' rating on the stock with a revised target price.</li></ul>

Amgen experienced a decent quarter of growth, with total revenues up 4% and volume up 8%, reflecting strong global demand for many of their innovative medicines, such as Repatha and Prolia, as well as their biosimilar offerings.The development of multi-specific drugs to make untractable targets tractable is one of its primary research and molecular engineering interests.We remain optimistic about Amgen’s future growth and maintain our 'Hold' rating on the stock with a revised target price.

Stock Market News, Outlooks, and Top Picks, Cappuccino Finance

Cappuccino Finance

Stock Market News, Outlooks, and Top Picks

Cappuccino Finance, provides Financial vignettes for your cappuccino break!

Fun & informational articles to read in 10 min or less.

Equity Bottom-Up

<ul><li>It’s a volatile market these days! The Omicron variant, interest rate hikes, supply chain disruption, and labor shortage are causing the market to fluctuate wildly</li><li>Healthcare companies provide essential services regardless of economic conditions.</li><li>The screener results were quite satisfactory. AbbVie, Amgen, and Merck. I like all of them!</li></ul>

It’s a volatile market these days! The Omicron variant, interest rate hikes, supply chain disruption, and labor shortage are causing the market to fluctuate wildlyHealthcare companies provide essential services regardless of economic conditions.The screener results were quite satisfactory. AbbVie, Amgen, and Merck. I like all of them!

Dividend HealthCare Stocks Screener – Jan 2022

<ul>
<li>Amgen continued to witness a decent top-line growth despite the lingering effects of the pandemic driven by the gradually increasing demand for its offerings.</li>
<li>The company’s total revenue grew by 5% in Q2 compared to the previous year and 11% compared to the previous quarter.</li>
<li>Sadly, a trimmed guidance for the rest of 2021 resulted in the stock price witnessing a strong correction.</li>
</ul>


Amgen continued to witness a decent top-line growth despite the lingering effects of the pandemic driven by the gradually increasing demand for its offerings.
The company’s total revenue grew by 5% in Q2 compared to the previous year and 11% compared to the previous quarter.
Sadly, a trimmed guidance for the rest of 2021 resulted in the stock price witnessing a strong correction.


IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Jacobio Pharmaceuticals / Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/jacobio-pharmaceuticals" target="_blank" data-smartkarma-citation="entities:29696:1" rel="noopener">Jacobio Pharmaceuticals (1588148D CH)</a> is a clinical-stage pharma company focusing on the in-house discovery and development of innovative oncology therapies. Jacobio’s strategy of “drugging the undruggable” is based on developing clinical-stage small-molecule drug candidates to modulate enzymes by binding to their allosteric sites. Jacobio is backed by Qiming Venture Partners, Hillhouse Capital, LAV, <a href="https://www.smartkarma.com/entities/center-laboratories-inc" target="_blank" data-smartkarma-citation="entities:10778:1" rel="noopener">Center Laboratories (4123 TT)</a> and CICC Capital Management. The Series C+ round in February 2020 raised $26.0 million at a post-money valuation of $455 million. </p><div class="content-highlight"><p>Jacobio is seeking to raise $300 million through a Hong Kong IPO. Jacobio is one of the few Chinese biotechs which have licensed out their drug candidates to leading global pharma companies such as <a href="https://www.smartkarma.com/entities/abbvie-inc" target="_blank" data-smartkarma-citation="entities:1135:1" rel="noopener">Abbvie Inc (ABBV US)</a>. Jacobio claims to have discovered several drug candidates with the potential to be among the first few market entrants in their respective drug classes globally. Overall, we believe that Jacobio’s clinical assets are attractive. </p></div>

Jacobio Pharmaceuticals (1588148D CH) is a clinical-stage pharma company focusing on the in-house discovery and development of innovative oncology therapies. Jacobio’s strategy of “drugging the undruggable” is based on developing clinical-stage small-molecule drug candidates to modulate enzymes by binding to their allosteric sites. Jacobio is backed by Qiming Venture Partners, Hillhouse Capital, LAV, Center Laboratories (4123 TT) and CICC Capital Management. The Series C+ round in February 2020 raised $26.0 million at a post-money valuation of $455 million. Jacobio is seeking to raise $300 million through a Hong Kong IPO. Jacobio is one of the few Chinese biotechs which have licensed out their drug candidates to leading global pharma companies such as Abbvie Inc (ABBV US). Jacobio claims to have discovered several drug candidates with the potential to be among the first few market entrants in their respective drug classes globally. Overall, we believe that Jacobio’s clinical assets are attractive. 

Jacobio Pharma IPO Initiation: Drugging the Undruggable

United States

Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Amgen Inc (AMGN US)

Amgen Inc.: Detailed Credit Analysis & Financial Strength Evaluation Report

Amgen has continued to benefit from strong global demand for many of their innovative medicines, such as Repatha and Prolia, as well as their...

Baptista Research

Amgen Inc.: Financial & Price Forecasts

Amgen experienced a decent quarter of growth, with total revenues up 4% and volume up 8%, reflecting strong global demand for many of their...

Baptista Research

Dividend HealthCare Stocks Screener – Jan 2022

It’s a volatile market these days! The Omicron variant, interest rate hikes, supply chain disruption, and labor shortage are causing the market to...

Cappuccino Finance

Amgen Inc. - Investment Thesis

Amgen continued to witness a decent top-line growth despite the lingering effects of the pandemic driven by the gradually increasing demand for...

Baptista Research

Jacobio Pharma IPO Initiation: Drugging the Undruggable

Jacobio is seeking to raise $300 million through a Hong Kong IPO. Overall, we believe that Jacobio’s clinical assets are attractive.

Arun George

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)